Transaction Details:

Hash 85527149e5e8c55019ab48fc28a597c1b23a5a43b79af185e4e776e5bd1a703d
Blockhash 2a3fdb49be336b797739ae8e4e8d6c05960e25a630152e0933b7ac26fc558ea8
Blocktime 2019-11-22 17:51
Confirmations 47832

Inputs

Index Previous Output Address
0 f372d5fdaf83ff5fb4ecacd71a0d6bb3b51578b95fa05c6c99b1421399374dd4:0 2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd

Outputs

Index Redeemed in Address Amount
0 Not yet redeemed N/A 0 CBL
1 Not yet redeemed 2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd 99.99982128 CBL
{
"txid": 85527149e5e8c55019ab48fc28a597c1b23a5a43b79af185e4e776e5bd1a703d,
"time": 1574445110,
"blocktime": 1574445110,
"blockhash": 2a3fdb49be336b797739ae8e4e8d6c05960e25a630152e0933b7ac26fc558ea8,
"confirmations": 47832,
"vin ": [
{
"sequence": 4294967295
"vout": 0
"txid": f372d5fdaf83ff5fb4ecacd71a0d6bb3b51578b95fa05c6c99b1421399374dd4
"scriptSig": {'hex': '473044022054df0e0c1d355089c4ffff6bfb0432db455dc1f2728a2149061cd571b37e06bc0220211d6348873b797631338cfcfb22dbe0e2a3b03b538e3a6aef47461c30230c4b012103f4157f5bbcf4594cb612f878fa622f4fa99713ebd638179751679d259fb49e38', 'asm': '3044022054df0e0c1d355089c4ffff6bfb0432db455dc1f2728a2149061cd571b37e06bc0220211d6348873b797631338cfcfb22dbe0e2a3b03b538e3a6aef47461c30230c4b01 03f4157f5bbcf4594cb612f878fa622f4fa99713ebd638179751679d259fb49e38'}
}
],
"vout ": [
{
"items": [
{'streamref': '22580-300-49565', 'publishers': ['2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd'], 'name': 'iscc', 'createtxid': '9dc120f0f3ba1bf3cc53010a0af74f164961f37595bdd9a89b5064e60304c070', 'keys': ['CCMPPnmFDzdNa', 'CTKTck2KkmD4h', 'CDeJ8d2yTfBML', 'CRZbiByj36kcU'], 'data': {'json': {'tophash': '4b4838e76c42243dc0c9a755717fd583cf5d64f27b6cb095a25a8098dae5fbd1', 'title': 'gefitinib with pemetrexed as firstline therapy in patients with advanced nonsquamous nonsmall cell lung cancer with activating e', 'meta': [{'schema': 'schema.org', 'data': {'encoding': [{'contentUrl': 'http://europepmc.org/articles/pmc5253295?pdf=render', '@type': 'MediaObject', 'encodingFormat': 'application/pdf'}], '@type': 'ScholarlyArticle', 'name': 'Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations', 'publisher': {'@type': 'Organization', 'name': 'AME Publishing Company'}, '@context': 'http://schema.org/', 'genre': 'journal-article', 'author': [{'@type': 'Person', 'name': 'Shinkyo Yoon'}, {'@type': 'Person', 'name': 'Dae Ho Lee'}, {'@type': 'Person', 'name': 'Sang-We Kim'}], 'datePublished': '2017-01-01', 'identifier': [{'@type': 'PropertyValue', 'value': '10.21037/atm.2016.12.64', 'propertyID': 'DOI'}, {'@type': 'PropertyValue', 'value': 'CCMPPnmFDzdNa-CTKTck2KkmD4h-CDeJ8d2yTfBML-CRZbiByj36kcU', 'propertyID': 'ISCC'}]}, 'mediatype': 'application/ld+json'}]}}, 'type': 'stream'}
],
"value": 0
"n": 0
"scriptPubKey": {
"hex": 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
"asm": 73706b65164ff70a0a0153ccf31bbaf3f020c19d OP_DROP 73706b6b43434d50506e6d46447a644e61 OP_DROP 73706b6b43544b54636b324b6b6d443468 OP_DROP 73706b6b4344654a386432795466424d4c OP_DROP 73706b6b43525a626942796a33366b6355 OP_DROP 73706b6602 OP_DROP OP_RETURN 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
"type": nulldata
}
},
{
"value": 99.99982128
"n": 1
"scriptPubKey": {
"reqSigs": 1
"addresses": ['2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd']
"hex": 76a91470f3924b82ad8ba9ca4b38ee85a83bd99c142f9f88ac
"asm": OP_DUP OP_HASH160 70f3924b82ad8ba9ca4b38ee85a83bd99c142f9f OP_EQUALVERIFY OP_CHECKSIG
"type": pubkeyhash
}
}
]
}